debt_leverage_profile
Near-zero long-term debt; primarily equity-financed via public markets; minimal interest burden on balance sheet as of 2023.
Inferred
Agent_Inference
interest_rate_sensitivity
Low sensitivity; negligible debt load means 20% rate rise has near-zero direct P&L impact; cash burn rate is primary risk.
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
1) China-based PCR/diagnostic reagent manufacturers; 2) Hong Kong logistics hub for Asia-Pacific distribution.
Inferred
Agent_Inference
international_expansion_readiness
Revenue concentrated in HKD (pegged to USD, low devaluation risk), GBP (moderate volatility), and emerging Asia FX; modest sovereign FX exposure.
Inferred
Agent_Inference
geographic_footprint
Operates across Hong Kong, UK, and Southeast Asia; HKD peg limits FX risk but GBP and regional EM currencies pose moderate devaluation exposure.
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Likely dependent on 1–2 Chinese reagent/kit OEM suppliers exceeding 30% of input costs; substitution possible but disruptive with 3–6 month lead times.
Inferred
Agent_Inference
business_model_type_primary
Cloud dependency appears low; diagnostic kits and testing services are primarily physical/lab-based; cloud disruption would affect data reporting, not core operations.
Inferred
Agent_Inference
business_model_type_secondary
Secondary digital services (health data platforms) could face 30-day migration risk but represent minority of revenue; operational continuity largely preserved.
Inferred
Agent_Inference
switching_cost_profile
Moderate API coupling risk; ViralCare app integrates with third-party health data APIs; switching cost is meaningful but not enterprise-grade lock-in.
Inferred
Agent_Inference
howey_test_risk_index
Primary revenue from diagnostic product sales and testing services; does not meet Howey Test criteria — no investment contract structure in revenue model.
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Handles health/biometric data across UK (GDPR) and Asia; GDPR compliance exposure is material given UK operations; CCPA exposure minimal with negligible US revenue.
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; niche diagnostics player with sub-1% market share in fragmented global testing market; no dominant market position.
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Predominantly transactional (~80–90% kit/test sales); minimal recurring revenue; institutional B2B contracts provide some multi-year stability but are not subscription-based.
Inferred
Agent_Inference
monetization_vector
Primary monetization via direct product sales of PCR/rapid antigen kits and outsourced testing services; secondary via ViralCare platform licensing.
Inferred
Agent_Inference
pricing_architecture
Cost-plus pricing on diagnostic kits; vulnerable to commodity reagent inflation and margin compression from low-cost Asian competitors undercutting on price.
Inferred
Agent_Inference
pricing_power_rating
Low pricing power; commodity diagnostic market with Chinese OEM competition; differentiation through speed/certification rather than brand premium.
Inferred
Agent_Inference
target_gross_margin_bracket
Estimated gross margin 30–45%; diagnostic kit distribution margins compressed by OEM input costs and competitive pricing pressure.
Inferred
Agent_Inference
churn_vulnerability_index
Low free-rider risk; physical diagnostic kits require purchase; no freemium model detected; institutional clients may churn post-pandemic demand normalization.
Inferred
Agent_Inference
headcount_cost_structure
Revenue growth is partially headcount-linear for lab/logistics operations; software/platform component offers sublinear scaling potential but remains small.
Inferred
Agent_Inference
marginal_cost_of_growth
Doubling revenue likely requires ~60–70% headcount increase due to lab ops and distribution; not yet at platform-scale economics.
Inferred
Agent_Inference
franchise_compliance_risk
Not a franchise model; N/A for franchise compliance drift.
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC likely rises due to B2B sales cycle length; institutional procurement dominates; unit economics improve only if platform mix increases.
Inferred
Agent_Inference
network_effect_present
Weak network effects; ViralCare app has potential for data network effects but user base too small to create defensible flywheel as of 2023.
Inferred
Agent_Inference
asset_efficiency_ratio
AI displacement risk is moderate; diagnostic interpretation and reporting functions are AI-automatable, potentially reducing lab technician headcount 20–30%.
Inferred
Agent_Inference
recession_resistance_tier
Moderate recession resistance; infectious disease testing demand is semi-essential but discretionary corporate/travel testing collapses in downturns.
Inferred
Agent_Inference
customer_segment_primary
B2B institutional clients: corporates, airlines, healthcare providers, and government agencies requiring bulk diagnostic testing.
Inferred
Agent_Inference
customer_segment_secondary
B2C via retail pharmacy and direct-to-consumer rapid test kits; secondary and shrinking post-COVID normalization.
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
Capex is modest and shifting from COVID-era testing infrastructure toward ViralCare digital platform and new pathogen detection product lines.
Inferred
Agent_Inference
sec_cik
0001885827
High
SEC-EDGAR
ticker
VRAX
High
SEC-EDGAR